Aligos Therapeutics, Inc. ALGS
At closeNov 4, 2026, 6:24 AM EST
Pre-market · Nov 4, 6:24 AM ET
- YTD
- -49.03%
- 1 year
- -36.92%
- Market cap
- 29.66M
- Revenue (ttm)
- 6.00M
- EPS (ttm)
- -7.41
- Shares out
- 3.46M
- Forward P/E
- -3.30
- YTD return
- -49.03%
- 1-year return
- -36.92%
- Volume
- 13.90K
- Avg volume
- 70.54K
- Open
- 4.65
- Previous close
- 4.60
- Day's range
- 4.65 – 4.95
- 52-week range
- 3.98 – 13.69
- Beta
- 2.12
- Price target
- 103.33 (+2075.4%)
- Earnings date
- Aug 6, 2024
2Y -4.73 (-49.89%)
Key statistics
- Enterprise value
- 77.15M
- PEG ratio
- 0.00
- Price / sales
- 23.54
- Price / book
- 2.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -60.80%
- Free cash flow
- -49.06M
- Total cash
- 74.92M
- Total debt
- 9.13M
- Return on equity
- -146.69%
- Short % of float
- 12.63%
- 50-day average
- 19.24
- 200-day average
- 16.32
Analyst view
- Target (low)
- 60.00
- Target (mean)
- 103.33
- Target (high)
- 175.00
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 6, 2024
Expected Aug 6, 2024. Consensus EPS estimate -3.67.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -2.15 | -3.07 | -0.92 | -42.79% |
| Aug 6, 2024 | Jun 1, 2024 | -4.00 | 0.75 | +4.75 | +118.75% |
| Aug 6, 2024 | Jun 1, 2024 | -4.00 | — | — | — |
| May 7, 2024 | Mar 1, 2024 | -4.75 | -5.50 | -0.75 | -15.79% |
| May 7, 2024 | Mar 1, 2024 | -4.75 | — | — | — |
| Mar 12, 2024 | Dec 1, 2023 | -6.75 | -5.50 | +1.25 | +18.52% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 19, 2024 | HC Wainwright & Co. | init | — | Buy |
| Jan 17, 2023 | Piper Sandler | main | — | Overweight |
| Jan 6, 2023 | Piper Sandler | up | Neutral | Overweight |
About Aligos Therapeutics, Inc.
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aligos.com
News
Your note
Sign in to keep a note on ALGS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEIGELMAN LEONID | President | Conversion of Exercise of derivative security | Oct 19, 2020 | 0 |
| BLATT LAWRENCE M | Chief Executive Officer | Stock Award(Grant) | Oct 24, 2023 | 2,120,630 |
| NOVO HOLDINGS A/S | Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 19, 2020 | 2,614,560 |
| NUECHTERLEIN CAROLE L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Oct 24, 2023 | 0 |
| SCOPA JAMES PAUL | Director | Stock Award(Grant) | Oct 24, 2023 | 183,083 |
| SYMONS JULIAN A | Officer | Conversion of Exercise of derivative security | Oct 19, 2020 | 394,064 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.78% | 315,095 | 12.40M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 7.12% | 255,573 | 10.05M | Sep 29, 2024 |
| Deep Track Capital, Lp | 6.80% | 244,110 | 9.60M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 6.10% | 218,813 | 8.61M | Sep 29, 2024 |
| Vivo Capital, LLC | 3.95% | 141,879 | 5.58M | Sep 29, 2024 |
| Woodline Partners LP | 2.56% | 91,971 | 3.62M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.47% | 52,795 | 2.08M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.35% | 12,390 | 487.42K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.31% | 11,019 | 433.49K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 4,361 | 171.56K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.09% | 3,150 | 123.92K | Oct 30, 2024 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.03% | 1,255 | 49.37K | Jul 30, 2024 |